Medgenics (MDGN) Misses Q3 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Medgenics Reports Third Quarter 2015 Financial Results
October 22, 2015 8:01 AM EDTAcquired Phase 2-Ready CNS asset, NFC-1 First of pipeline of potential programs from CHOP collaboration Results of Phase 1 GREAT trial to be presented at American Academy of Child and Adolescent Psychiatry (AACAP) meeting Completed Successful Public Offering for $46M in gross proceeds
PHILADELPHIA, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE: MDGN) (the Company) today announced financial results for the three and nine months ended September 30, 2015.Â
Management... More
